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Fc-receptors (FcR) are widely expressed on cells of the
immune system. FcμR is a transmembrane protein with
an extracellular Ig-like domain homologous to the FcR for
both IgA and IgM (Fca/μR) and the polymeric Ig receptor
(pIgR). FcμR is expressed on CD19+B cells, CD4+/CD8+
T cells, and CD56+/CD3- NK cells. In addition, several
groups have reported that FcμR is overexpressed in
chronic lymphocytic leukemia (CLL) cells. Using immuno-
fluorescence staining, we found that FcμR can rapidly
uptake IgM, internalize it in specific vesicles and transport
it through the endocytic pathway to the lysosomal com-
partment. Interestingly, aggregation of FcμR with IgM
leads to rapid internalization of IgM (>80% internalized
within 5 minutes) whereas mAb bound FcμR is not inter-
nalized. Overexpression on CLL cells and rapid internali-
zation of FcμR represents a potential means of selectively
delivering a cytotoxic agent into malignant cells. To this
end, we engineered a protein scaffold derived from the
CH2-CH3-CH4 IgM constant regions with a C-terminal
selenocysteine that allows covalent conjugation of drugs
or toxins to the protein scaffold. We verified that the scaf-
fold also binds FcμR, is rapidly internalized and has a
serum circulatory half-life comparable to IgM (~18hrs) in
NOD/SCID/IL-2Rgnull (NSG) mice. We then demon-
strated that the scaffold, when conjugated to a cytotoxic
small molecule, kills malignant B cells, but not normal
T cells, from CLL patients in vitro and in NSG mice.
These findings indicate that the rapid internalization of
IgM-FcμR complexes can be exploited for therapeutic
purposes. Taken together, IgM-derived protein scaffold
antibody-drug conjugates appear as promising treatment
modalities for CLL and possibly other malignancies.
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